Clinical Characteristics of Talaromyces Marneffei Disease and Disseminated Nontuberculosis Mycobacterium Disease in AIDS Patients
-
摘要:
目的 比较艾滋病患者中马尔尼菲篮状菌病与播散性非结核分枝杆菌病患者的临床特征差异及预后的影响因素。 方法 回顾性收集上海市公共卫生临床中心2015年至2021年艾滋病患者中马尔尼菲篮状菌病为TM组,播散性非结核分枝杆菌病为NTM组,比较2组患者间的临床特征,同时分析预后的影响因素。 结果 2组患者平均年龄均小于40岁,NTM组24%患者预后不良,TM组预后不良占17%。相比于NTM组,TM组患者白蛋白更低(P = 0.003),降钙素原更高(P = 0.002),血沉更慢(P = 0.011),真菌D葡聚糖更高(P < 0.001)。NTM组患者内毒素越低,预后不良的风险越高(P = 0.022);白蛋白 < 30 g/L的患者预后不良的风险高于白蛋白 > 30 g/L的患者(P = 0.017);CD8 < 250/µL的患者预后不良的风险高于CD8 > 250/µL的患者(P = 0.049)。TM组CD8 < 250/µL的患者预后不良的风险高于CD8 > 250/µL的患者(P = 0.012);真菌D葡聚糖越低,预后不良的风险越高(P = 0.016)。 结论 在艾滋病患者中,与播散性非结核分枝杆菌相比,马尔尼菲篮状菌感染者白蛋白更低,血沉相对较慢,真菌D葡聚糖水平明显升高且有利于患者预后。2组患者预后均较差,较高的CD8水平预示着较好的预后。 Abstract:Objective To compare the clinical characteristics and analyzing the risk factors for poor prognosis of Talaromyces Marneffei and disseminated Nontuberculosis Mycobacterium disease in AIDS patients . Methods We retrospectively collected the data of cases of Talaromyces Marneffei and disseminated Nontuberculosis Mycobacterium disease in Shanghai Public Health Clinical Center from 2015 to 2021. Then we compared the differences of clinical characteristics between the two groups, the risk factors for poor prognosis were also analyzed. Results The mean age in both groups were younger than 40 years and, the proportion of poor prognosis in NTM group was 24% while it was 17% in TM group. Compared to the NTM group, serum albumin was lower in group TM (P = 0.003), Procalcitonin was higher (P = 0.002), slower ESR (P = 0.011), fungal D-glucan was higher (P < 0.001). When CD8 less than 250/µL, the risk of poor prognosis was higher than patients with CD8 > 250/µL (P = 0.049) in the NTM group. Albumin < 30 g/L (P = 0.017) or endotoxin < 6 pg/ml (P = 0.022) were both independent risk factors for poor prognosis in the NTM group. The fungal D glucan less than 11pg/mL (P = 0.016) or CD8 < 250/µL (P = 0.012) were both independent risk factors for poor prognosis in the TM group. Conclusions In AIDS patients, people infected with Talaromyces Marneffei have lower albumin than disseminated Nontuberculous Mycobacterium and need to pay close attention to timely supplement. Cases in both TM and NTM groups have high mortality. Higher levels of CD8 indicate a better prognosis. -
Key words:
- HIV /
- AIDS /
- Talaromyces Marneffei /
- Non-tuberculous Mycobacteria /
- Clinical characteristics /
- Prognosis
-
表 1 艾滋病合并马尔尼菲篮状菌与非结核分枝杆菌患者临床特征比较[
$ \bar x \pm s $ /M(P25,P75)/n(%)]Table 1. Comparison of the clinical characteristics of Talaromyces Marneffei and disseminated Nontuberculosis Mycobacterium disease in AIDS patients . [
$ \bar x \pm s $ /M(P25,P75)/n(%)]指标 正常范围 NTM组(n = 169 ) TM组(n = 87) F/U/χ2 P 年龄 (岁) − 38.0 ± 11.1 36.5 ± 10.9 0.001 0.976 男性 − 161(95.3) 81(93.1) 0.52 0.471 白细胞 (×109/L) 3.5~9.5 4.0(2.6,5.5) 3.4(2.4,5.1) 6.84 0.396 中性粒细胞 (×109/L) 1.80~6.30 2.9(1.8,4.5) 2.9(1.7,4.2) 6.93 0.493 血红蛋白 (g/L) 115~150 87.5(68.2,105.7) 94(81,107) 8.31 0.071 CD4 (/µL) 410~1590 8(3,19) (n = 168) 7(4,19) (n = 84) 7.09 0.938 CD8 (/µL) 190~1140 261(121,468)(n = 160) 202(98,335)(n = 82) 5.67 0.085 CD4/CD8比值 0.9~3.6 0.03(0.0,0.08)(n = 160) 0.04(0.02,0.09)(n = 82) 7.51 0.066 白蛋白 (g/L) 40~55 30.0(26.0,33.5) 27.0(23.4,31.0)(n = 86) 5.62 0.002* C反应蛋白 (mg/L) 0~10 39.9(17.9,93.7)(n = 140) 53.7(26.3,88.2)(n = 76) 5.83 0.245 降钙素原 (ng/mL) 0~0.05 0.24(0.1,0.8) (n = 154) 0.63(0.2,1.7) (n = 74) 6.96 0.002* 血沉 (mm/h) 0~15 78(54,96) (n = 103) 64.0(41.0,83.7) (n = 54) 2.09 0.011* 真菌D葡聚糖 (pg/mL) < 60 10(10,128) (n = 155) 199.0(48.5,272.5)(n = 76) 8.71 < 0.001* 内毒素(pg/mL) < 10 6.0(5.0,20.8) (n = 142) 5.1(5.0,10.2) (n = 66) 4.39 0.435 预后不良(%) − 41(24.3) 15(17.2) 1.66 0.198 *P < 0.05。 表 2 艾滋病合并播散性非结核分枝杆菌患者预后的影响因素
Table 2. Risk factors for poor prognosis of disseminated Nontuberculosis Mycobacterium disease in AIDS patients
因素 B Wald χ2 OR 95%CI P 内毒素 −1.018 5.246 0.361 0.151~0.863 0.022 白蛋白 −1.079 5.676 0.340 0.140~0.826 0.017 CD8 −0.850 3.860 0.427 0.183~0.998 0.049 常量 3.104 8.875 22.285 0.003 表 3 艾滋病合并马尔尼菲篮状菌患者预后的影响因素
Table 3. Risk factors for poor prognosis of Talaromyces Marneffei disease in AIDS patients
因素 B Wald χ2 OR 95%CI P CD8 −2.814 6.330 0.060 0.007~0.537 0.012 真菌D葡聚糖 −1.874 5.858 0.153 0.034~0.700 0.016 常量 4.588 6.332 98.345 0.012 -
[1] Chaisson R E,Gallant J E,Keruly J C,et al. Impact of opportunistic disease on survival in patients with HIV infection[J]. AIDS,1998,12(1):29-33. doi: 10.1097/00002030-199801000-00004 [2] Pruksaphon K,Intaramat A,Ratanabanangkoon K,et al. Development and characterization of an immunochromatographic test for the rapid diagnosis of Talaromyces (Penicillium) marneffei[J]. PLoS One,2018,13(4):e195596. [3] Nong S,Liang J. Bone marrow Penicillium marneffei infection in acquired immunodeficiency syndrome patients:report of 35 cases[J]. Trop Biomed,2013,30(1):89-91. [4] 周昌静,黄卫娥,余小舒. 45例艾滋病合并马尔尼菲青霉病临床特征分析[J]. 中国性科学,2021,30(05):140-142. doi: 10.3969/j.issn.1672-1993.2021.05.041 [5] Armstrong-James D,Meintjes G,Brown G D. A neglected epidemic:fungal infections in HIV/AIDS[J]. Trends Microbiol,2014,22(3):120-127. doi: 10.1016/j.tim.2014.01.001 [6] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心,李太生. 中国艾滋病诊疗指南(2021年版)[J]. 中国艾滋病性病,2021,27(11):1182-1201. [7] 宋炜,刘莉,卢洪洲. 艾滋病合并分枝杆菌感染患者分枝杆菌菌种鉴定[J]. 浙江大学学报(医学版),2016,45(03):243-248. [8] Hu Y,Zhang J,Li X,et al. Penicillium marneffei infection:an emerging disease in Mainland of China[J]. Mycopathologia,2013,175(1-2):57-67. doi: 10.1007/s11046-012-9577-0 [9] Alvaro-Meca A,Rodriguez-Gijon L,Diaz A,et al. Trends in nontuberculous mycobacterial disease in hospitalized subjects in Spain (1997-2010) according to HIV infection[J]. HIV Med,2015,16(8):485-493. doi: 10.1111/hiv.12251 [10] Kobayashi T,Nishijima T,Teruya K,et al. High mortality of disseminated non-tuberculous mycobacterial infection in HIV-infected patients in the antiretroviral therapy era[J]. PLoS One,2016,11(3):e151682. [11] 吴跃,邓西子,胡凤玉,等. AIDS合并播散性非结核分枝杆菌病的临床特征与死亡危险因素分析[J]. 中国艾滋病性病,2017,23(11):999-1001. [12] Jiang J,Meng S,Huang S,et al. Effects of talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China:a retrospective cohort study[J]. Clin Microbiol Infect,2019,25(2):233-241. doi: 10.1016/j.cmi.2018.04.018 [13] Polo M L,Ghiglione Y A,Salido J P,et al. Liver cirrhosis in HIV/HCV-coinfected individuals is related to NK cell dysfunction and exhaustion,but not to an impaired NK cell modulation by CD4(+) T-cells[J]. J Int AIDS Soc,2019,22(9):e25375. [14] 夏晓寒,黄丁. 外周血血浆中甲胎蛋白、丙酮酸激酶M2和白蛋白mRNA检测在乙型肝炎肝硬化患者早期诊断中的价值[J]. 世界华人消化杂志,2014,22(13):1876-1880. [15] 杨丹丹,张桂仙,赵自屹,等. 艾滋病合并马尔尼菲篮状菌感染的流行病学及临床特点分析[J]. 中国病原生物学杂志,2020,15(05):497-502. [16] Oberhoffer M,Stonans I,Russwurm S,et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro[J]. J Lab Clin Med,1999,134(1):49-55. doi: 10.1016/S0022-2143(99)90053-7 [17] Michel L. Handbook of spine surgery - second edition[J]. Acta Chir Belg,2016,116(4):267. doi: 10.1080/00015458.2016.1181324 [18] Kedzierska A,Kochan P,Pietrzyk A,et al. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans:Galactomannan,mannan and (1->3)-beta-D-glucan antigens[J]. Eur J Clin Microbiol Infect Dis,2007,26(11):755-766. doi: 10.1007/s10096-007-0373-6 [19] 左向华,陈建魁,于农,等. 侵袭性真菌感染患者1,3-β-D葡聚糖检测的临床价值[J]. 国际检验医学杂志,2010,31(03):220-221. doi: 10.3760/cma.j.issn.1673-4130.2010.03.005 [20] Cao W,Mehraj V,Kaufmann D E,et al. Elevation and persistence of CD8 T-cells in HIV infection:the Achilles heel in the ART era[J]. J Int AIDS Soc,2016,19(1):20697. doi: 10.7448/IAS.19.1.20697 [21] Helleberg M,Kronborg G,Ullum H,et al. Course and clinical significance of CD8+ T-cell counts in a large cohort of HIV-infected individuals[J]. J Infect Dis,2015,211(11):1726-1734. doi: 10.1093/infdis/jiu669 [22] Sun J,Sun W,Tang Y,et al. Clinical characteristics and risk factors for poor prognosis among HIV patients with Talaromyces marneffei bloodstream infection[J]. BMC Infect Dis,2021,21(1):514. doi: 10.1186/s12879-021-06232-2